Spark BioPharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Spark BioPharma, Inc. - overview
Established
2016
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Founded in 2016 and based in Seoul, South Korea, Spark BioPharma, Inc. develops a technology platform for drug screening and target identification for anti-cancer drug candidates. In April 2022, Spark BioPharma, Inc. raised KRW 25 billion in series C funding from returning investors Company K Partners, IMM Investment, KB Investment, and KTB Network, and new investors DT&Investment, Kiwoom Investment, Medytox Venture Investment, Shinhan Venture Investment, Time Folio Asset Management, and We Venture Partners.
The April investment will help Spark BioPharma, Inc. with its domestic and overseas clinical trials and develop technology exported to global pharmaceutical companies.
Current Investors
KB Investment, Solidus Investment, Korea Tech Incubator for Startup
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.sparkbio.kr
Verticals
E-commerce, Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
Spark BioPharma, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.